The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Open accessAbstract
Background: Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been associated with increased HF risk. We performed secondary analyses of HF and related outcomes with the dipeptidyl peptidase-4 inhibitor linagliptin versus placebo in CARMELINA (The Cardiovascular and Renal Microvascular Outcome Study With Linagliptin), a cardiovascular outcomes trial that enrolled participants with type 2 diabetes mellitus and atherosclerotic cardiovascular disease and/or kidney disease. Methods: Participants in 27 countries with type 2 diabetes mellitus and concomitant atherosclerotic cardiovascular disease and/or kidney disease were randomized 1:1 to receive once daily oral linagliptin 5 mg or placebo, on top of standard of care. All hospitalization for HF (hHF), cardiovascular outcomes, and deaths were prospectively captured and centrally adjudicated. In prespecified and post hoc analyses of HF and related events, Cox proportional hazards models adjusting for region and baseline history of HF were used. Recurrent hHF events were analyzed using a negative binomial model. In a subset of participants with left ventricular ejection fraction captured within the year before randomization, HF-related outcomes were assessed in subgroups stratified by left ventricular ejection fraction > or ≤50%. Results: CARMELINA enrolled 6979 participants (mean age, 65.9 years; estimated glomerular filtration rate, mL/min per 1.73m 2 ; hemoglobin A1c, 8.0%; 62.9% men; diabetes mellitus duration, 14.8 years), including 1873 (26.8%) with a history of HF at baseline. Median follow-up was 2.2 years. Linagliptin versus placebo did not affect the incidence of hHF (209/3494 [6.0%] versus 226/3485 [6.5%], respectively; hazard ratio [HR], 0.90; 95% CI, 0.74–1.08), the composite of cardiovascular death/hHF (HR, 0.94; 95% CI, 0.82–1.08), or risk for recurrent hHF events (326 versus 359 events, respectively; rate ratio, 0.94; 95% CI, 0.75–1.20). There was no heterogeneity of linagliptin effects on hHF by history of HF at baseline, baseline estimated glomerular filtration rate or urine albumin-creatinine ratio, or prerandomization left ventricular ejection fraction. Conclusions: In a large, international cardiovascular outcome trial in participants with type 2 diabetes mellitus and concomitant atherosclerotic cardiovascular disease and/or kidney disease, linagliptin did not affect the risk of hHF or other selected HF-related outcomes, including among participants with and without a history of HF, across the spectrum of kidney disease, and independent of previous left ventricular ejection fraction. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01897532.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These observations led to the development and regulatory filing of prospective HF analysis plans for the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) and CARMELINA (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus) trials, each of which revealed no increased risk of HF with either sitagliptin or linagliptin”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [179]
In the citing paper
“Sitagliptin and linagliptin had a neutral effect.174,[178][179][180]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [179]
In the citing paper
“In addition, data from the CAROLINA trial comparing linagliptin (shown to not increase the risk of HF hospitalization vs. placebo in the CARMELINA trial) vs. glimepiride did not show an elevated risk of HF hospitalization by this sulphonylurea.179”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [179]
In the citing paper
“In addition, data from the CAROLINA trial comparing linagliptin (shown to not increase the risk of HF hospitalization vs. placebo in the CARMELINA trial) vs. glimepiride did not show an elevated risk of HF hospitalization by this sulphonylurea.179”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [179]
In the citing paper
“Subsequent observational studies, CVOTs, and meta-analyses have not shown an excess heart failure risk with DPP4 inhibitors.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationRosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Self-citationZannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Self-citation2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
Hicks, K. A., Tcheng, J. E., Bozkurt, B., CHAITMAN, B. R., Cutlip, D. E., Farb, A. A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000156 · Cited by 712
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Flagged first, then by citations
Cited by
Sorted by citations
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationRosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Self-citationTan, Y., Zhang, Z., Zheng, C., Wintergerst, K. A., Keller, B. B., & Cai, L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0339-2 · Cited by 862
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 459
Pop‐Busui, R., Januzzi, J. L., Bruemmer, D., Butalia, S., Green, J. B., Horton, W. B., Knight, C. M., Levi, M., Rasouli, N., & Richardson, C. R. (2022) · Diabetes Care · doi:10.2337/dci22-0014 · Cited by 442
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Segar, M. W., Vaduganathan, M., Patel, K. V., McGuire, D. K., Butler, J., Fonarow, G. C., Basit, M. A., Kannan, V., Grodin, J. L., Everett, B. M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0587 · Cited by 307
Self-citationMakrilakis, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152720 · Cited by 233
SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Lam, C. S. P., Chandramouli, C., Ahooja, V., & Verma, S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013389 · Cited by 200
Seferovic, P. M., Coats, A. J. S., Ponikowski, P. P., Filippatos, G. S., Huelsmann, M., Jhund, P. S., Polovina, M. M., Michel Komajda, N., Seferović, J. P., Sarı, İ., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1673 · Cited by 183
The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Lytvyn, Y., Bjornstad, P., van Raalte, D. H., Heerspink, H. J. L., & Cherney, D. Z. I. (2019) · Endocrine Reviews · doi:10.1210/endrev/bnz010 · Cited by 170
Marso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.063 · Cited by 118
Sharma, A., Pagidipati, N. J., Califf, R. M., McGuire, D. K., Green, J. B., DeMets, D., George, J. T., Gerstein, H. C., Hobbs, T. M., Holman, R. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041022 · Cited by 111
Self-citationFudim, M., White, J., Pagidipati, N. J., Lokhnygina, Y., Wainstein, J., Murin, J., Iqbal, N., Öhman, P., Lopes, R. D., Reicher, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041659 · Cited by 99
Metabolism and Chronic Inflammation: The Links Between Chronic Heart Failure and Comorbidities
Li, Z., Zhao, H., & Wang, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.650278 · Cited by 102
Leveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 84
Bell, D. S. H., & Gonçalves, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13652 · Cited by 75
McGuire, D. K., Zinman, B., Inzucchi, S. E., Wanner, C., FITCHETT, D. H., Anker, S. D., Pocock, S., Kaspers, S., George, J. T., von Eynatten, M., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30344-2 · Cited by 76
Self-citationKanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · UCL Discovery (University College London) · Cited by 71
Gupta, S., & Sen, U. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104391 · Cited by 74
Bashier, A. M., Hussain, A. K. B., Abdelgadir, E., Alawadi, F., Sabbour, H. M., & CHILTON, R. J. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0476-0 · Cited by 63
Packer, M. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.09.002 · Cited by 65
Piepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2351 · Cited by 73
Epidemiology of heart failure in diabetes: a disease in disguise
Hoek, A. G., Canto, E. D., Wenker, E., Bindraban, N. R., Handoko, M. L., Elders, P. J. M., & Beulens, J. W. J. (2024) · Diabetologia · doi:10.1007/s00125-023-06068-2 · Cited by 73
Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0279 · Cited by 62
Self-citationKanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 80
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 60
Butler, J., Handelsman, Y., Bakris, G. L., & Verma, S. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1708 · Cited by 54
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Pedroso Camargos, A., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.069 · Cited by 47
The future of new drugs for diabetes management
Bailey, C. J., & Day, C. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107785 · Cited by 48
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 45
Lamos, E. M., Hedrington, M. S., & Davis, S. N. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1626823 · Cited by 39
Piepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab147 · Cited by 43
Hanssen, N. M. J., & Jandeleit-Dahm, K. A. M. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119842339 · Cited by 39
Reappraisal on pharmacological and mechanical treatments of heart failure
Liang, B., Zhao, Y.-X., Zhang, X., Liao, H.-L., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01024-5 · Cited by 39
Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
Cheng, Q., Cheng, J., Cordato, D. J., & Gao, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107559 · Cited by 34
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 30
Ramos, M., FOOS, V., Ustyugova, A., Hau, N., Gandhi, P., & Lamotte, M. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00701-3 · Cited by 31
Lingvay, I., Beetz, N., Sennewald, R., Schuler‐Metz, A., Bertulis, J., Loley, C., Lang, B. J., Lippert, C., Lee, J., Manning, L. S., et al. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1750228 · Cited by 31
Yang, D.-Y. D., He, X., Liang, H., Zhang, S., Zhong, X., Luo, C., Du, Z., He, J., Zhuang, X., & Liao, X. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0853-x · Cited by 29
Contemporary Management of Heart Failure in Patients With Diabetes
Shaw, J. A., & Cooper, M. E. (2020) · Diabetes Care · doi:10.2337/dc20-2173 · Cited by 29
Self-citationRoles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
Cao, F., Wu, K., Zhu, Y., & Bao, Z.-W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.731273 · Cited by 34
Cao, H., Liu, T., Wang, L., & Ji, Q. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14702 · Cited by 28
Cooper, M. E., Rosenstock, J., Kadowaki, T., Seino, Y., Wanner, C., Schnaidt, S., Clark, D., Johansen, O. E., & CARMELINA investigators (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13995 · Cited by 27
Self-citationNauck, M. A., McGuire, D. K., Pieper, K. S., Lokhnygina, Y. V., Strandberg, T. E., Riefflin, A., Delibaşı, T., Peterson, E. D., White, H. D., Scott, R. S., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0921-2 · Cited by 25
Self-citationA Glimpse of Inflammation and Anti-Inflammation Therapy in Diabetic Kidney Disease
Liu, C., Yang, M., Li, L., Luo, S., Yang, J., Li, C., Liu, J., & Sun, L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.909569 · Cited by 28
Inagaki, N., Yang, W., Watada, H., Ji, L., Schnaidt, S., Pfarr, E., Okamura, T., Johansen, O. E., George, J. T., von Eynatten, M., et al. (2019) · Diabetology International · doi:10.1007/s13340-019-00412-x · Cited by 22
Self-citationAbuhasira, R., Ayalon‐Dangur, I., Zaslavsky, N., Koren, R., Keller, M., Dicker, D., & Grossman, A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.794382 · Cited by 23
Darsalia, V., Johansen, O. E., Lietzau, G., Nyström, T., Klein, T., & Patrone, C. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00493 · Cited by 23
Self-citationAguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 25
New antidiabetic therapy and HFpEF: light at the end of tunnel?
Tadić, M., Sala, C., Saeed, S., Grassi, G. M., Mancia, G., Rottbauer, W., & Cuspidi, C. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10106-9 · Cited by 23
Richardson, T. L., Halvorson, A. E., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Grijalva, C. G., Elasy, T. A., & Roumie, C. L. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2751 · Cited by 22
Predictors of heart failure development in type 2 diabetes
Verma, S., Sharma, A., Kanumilli, N., & Butler, J. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000647 · Cited by 22
Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice
Hsuan, C., Teng, S. I. F., Hsu, C., Liao, D., Chang, A. J.-W., Lee, H.-L., Hee, S., Chang, Y., & Chuang, L. (2023) · Biomedicines · doi:10.3390/biomedicines11030662 · Cited by 23
Nassif, M. E., & Kosiborod, M. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.025 · Cited by 20
Mikov, M., Pavlović, N., Stanimirov, B., Đanić, M., Goločorbin-Kon, S., Stankov, K., & Al‐Salami, H. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00570-y · Cited by 23
Kato, E. T., & Kimura, T. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0013 · Cited by 21
How Diabetes and Heart Failure Modulate Each Other and Condition Management
Randhawa, V. K., Dhanvantari, S., & Connelly, K. A. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.11.014 · Cited by 20
Guardado‐Mendoza, R., Garcia-Magaña, M. A., Martínez-Navarro, L. J., Macías-Cervantes, H. E., Aguilar-Guerrero, R., Suárez-Pérez, E. L., & Aguilar-García, A. (2022) · Scientific Reports · doi:10.1038/s41598-021-04511-1 · Cited by 21
Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy
Butler, J., Januzzi, J. L., & Rosenstock, J. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14042 · Cited by 19
Self-citationAugestad, I. L., Pintana, H., Larsson, M., Krizhanovskii, C., Nyström, T., Klein, T., Darsalia, V., & Patrone, C. (2020) · Diabetes · doi:10.2337/db20-0095 · Cited by 19
Pan, X., Xu, S., Li, J., & Tong, N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.599355 · Cited by 20
Wanner, C., Cooper, M. E., Johansen, O. E., Toto, R. D., Rosenstock, J., McGuire, D. K., Kahn, S. E., Pfarr, E., Schnaidt, S., von Eynatten, M., et al. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa225 · Cited by 18
Self-citationAdeghate, E. A., Kalász, H., Jaberi, S. A., Adeghate, J. O., & Tekes, K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1865914 · Cited by 19
Dhabhai, B., Dhakar, R., Ranga, V., Surolia, P. K., Menon, A. M., Sharma, N. K., Dakal, T. C., & Lohar, D. (2023) · Medinformatics · doi:10.47852/bonviewmedin32021408 · Cited by 18
Woo, V. C., Connelly, K. A., Lin, P., & McFarlane, P. A. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1576479 · Cited by 17
Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
Jerkins, T. W., McGill, J. B., & Bell, D. S. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15062 · Cited by 19
Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure
Zannad, F. M., & Rossignol, P. (2019) · Circulation · doi:10.1161/circulationaha.118.038399 · Cited by 15
The role of multimodality imaging in diabetic cardiomyopathy: a brief review
Adel, F., & Chen, H. H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1405031 · Cited by 14
Savarese, G., Schrage, B., Cosentino, F., Lund, L. H., Rosano, G. M. C., Seferovic, P. M., & Butler, J. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12937 · Cited by 14
Standl, E., & Schnell, O. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108054 · Cited by 14
Can Newer Anti-Diabetic Therapies Delay the Development of Diabetic Nephropathy?
Aziz, S., Ghadzi, S. M. S., Sulaiman, S. A. S., Hanafiah, N. H. M., & Harun, S. N. (2021) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_497_21 · Cited by 13
Pinto, L. C. F., Rados, D. R. V., Remonti, L. R., Viana, L. V., Pulz, G. T. C., Carpena, M. P., Borges, R. P., Marobin, R., Beretta, M. V., Pedrollo, E. F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa534 · Cited by 13
Campos, C., & Unger, J. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1971461 · Cited by 13
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 15
Yandrapalli, S., Jolly, G. P., Horblitt, A. M., Pemmasani, G., Sanaani, A., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000308 · Cited by 12
Kadowaki, T., Yamamoto, F., Taneda, Y., Naito, Y., Clark, D., Lund, S. S., Okamura, T., & Kaku, K. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1898585 · Cited by 12
Guardado‐Mendoza, R., Cázares-Sánchez, D., Evia-Viscarra, M. L., Jiménez-Ceja, L. M., Pérez, E. G. D., & Aguilar-García, A. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107864 · Cited by 12
Batchu, S. N., Yerra, V. G., Liu, Y., Advani, S. L., Klein, T., & Advani, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165756 · Cited by 12
Cavallari, I., Maddaloni, E., Pieralice, S., Mulè, M. T., Buzzetti, R., Ussia, G. P., Pozzilli, P., & Grigioni, F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa427 · Cited by 12
What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Khan, M. S., & Vaduganathan, M. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01347-3 · Cited by 10
Scirica, B. M., Im, K., Murphy, S. A., Kuder, J., Rodriguez, D. A., Lópes, R. D., Green, J. B., Ruff, C. T., & Sabatine, M. S. (2022) · Clinical Cardiology · doi:10.1002/clc.23844 · Cited by 10
Yandrapalli, S., Malik, A. H., Horblitt, A. M., Pemmasani, G., Aronow, W. S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000311 · Cited by 9
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationAlvarez-Canales, M. F. D. L. L., Salazar-López, S. S., Farfán-Vázquez, D., Martínez-López, Y. E., González-Mena, J. N., Jiménez-Ceja, L. M., Vargas‐Ortiz, K., Evia-Viscarra, M. L., de Oca-Loyola, M. L. M., Folli, F. B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88108-8 · Cited by 8
Bain, S. C., Bakhai, A., Evans, M., Green, A., Menown, I. B. A., & Strain, W. D. (2019) · Diabetic Medicine · doi:10.1111/dme.14058 · Cited by 9
Vaduganathan, M., Singh, A., Sharma, A., Januzzi, J. L., Scirica, B. M., Butler, J., Zannad, F. M., McGuire, D. K., Cannon, C. P., & Bhatt, D. L. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.01.053 · Cited by 8
Self-citationEvidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials
Tanaka, A., & Node, K. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0834-0 · Cited by 8
CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle
Schernthaner, G., Wanner, C., Jurišić‐Eržen, D., Guja, C., Gumprecht, J., Jarek-Martynowa, I. R., Karasik, A., Lalic, N. M., Mankovsky, B., Prázný, M., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.013 · Cited by 9
Self-citationTanaka, A., & Node, K. (2020) · Diabetology International · doi:10.1007/s13340-020-00445-7 · Cited by 7
Al‐Salameh, A., Bouzegaoui, N. E., & Saraval, M. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.09.023 · Cited by 11
Lee, M. M. Y., & Sattar, N. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15085 · Cited by 11
Tomović, K., Anderluh, M., & Šmelcerović, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1642333 · Cited by 7
Nassif, M. E., & Kosiborod, M. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.003 · Cited by 6
Jeon, W. K., Kang, J., Kim, H.-S., & Park, K. W. (2021) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2021.10.2.210 · Cited by 7
RetractedKato, E. T., Das, S. R., & McGuire, D. K. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.12.010 · Cited by 7
Self-citationA drug mix and dose decision algorithm for individualized type 2 diabetes management
Nambiar, M., Bee, Y. M., Chan, Y. E., Mien, I. H., Guretno, F., Carmody, D., Lee, P. C., Chia, S. Y., Salim, N. N. M., & Krishnaswamy, P. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01230-5 · Cited by 8
Carrasco-Ruiz, M. F., Ruiz-Rivera, A., Soriano-Ursua, M. A., Martinez-Hernandez, C., Manuel‐Apolinar, L., Castillo‐Hernandez, C., Guevara‐Balcázar, G., Farfán‐García, E. D., Mejia-Ruiz, A., Rubio‐Gayosso, I., et al. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i4.239 · Cited by 6
Metadata
- Authors
- McGuire, D. K., Alexander, J. H., Johansen, O. E., Perkovic, V., Rosenstock, J., Cooper, M. E., Wanner, C., Kahn, S. E., Toto, R. D., Zinman, B., Baanstra, D., Pfarr, E., Schnaidt, S., Meinicke, T., George, J. T., von Eynatten, M., Marx, N., & On behalf of the CARMELINA Investigators
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Duke University (US)
- Boehringer Ingelheim (Norway) (NO)
- UNSW Sydney (AU)
- Dallas Diabetes Research Center (US)
- Monash University (AU)
- Universitätsklinikum Würzburg (DE)
- University of Washington (US)
- Mount Sinai Hospital (CA)
- Boehringer Ingelheim (Netherlands) (NL)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim International, Ingelheim, Germany (J.T.G., M.v.E.).
- Universitätsklinikum Aachen (DE)
- Corresponding author
- McGuire, Darren K.
- ORCID
- Venue
- Circulation
- Published
- 2019-01-15
- Volume
- 139
- Issue
- 3
- Pages
- 351-361
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2900102850
- Cited by
- 164
- References
- 22
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 9 · 2023: 10 · 2022: 17 · 2021: 22 · 2020: 51 · 2019: 37
- FWCI
- 25.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- linagliptin, heart failure, type 2 diabetes, DPP-4 inhibitors, atherosclerotic cardiovascular disease, kidney disease, cardiovascular outcomes, heart failure hospitalization, left ventricular ejection fraction, cardiovascular mortality, heart failure recurrence, renal outcomes, cardiovascular risk stratification
- MeSH terms
- Linagliptin, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glomerular Filtration Rate, Heart Failure, Glycated Hemoglobin, Humans, Kidney, Kidney Diseases, Male, Middle Aged, Prospective Studies, Risk Factors, Time Factors, Biomarkers, Prevalence, Treatment Outcome, Risk Assessment, Atherosclerosis, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
